Title: Integration of Nano- and Biotechnology for Beta-cell and Islet Transplantation

Website of the project: http://inanobit.eu/
Project number: H2020-NMBP-15-2017-760986
Call for Nanotechnologies, Advanced Materials
Biotechnology and Production
Number of participants: 8                      
Project Start Date: 01/10/2017
Duration: 5 years
End Date: 31/03/2023


The iNanoBIT project is aimed to apply nanotechnologies for imaging porcine pancreatic islet cellular transplants and induced pluripotent stem cell-derived beta-cells and subsequent regenerative processes in vivo in a porcine model. The project will develop1) novel highly sensitive nanotechnology-based imaging approaches allowing for monitoring of survival, engraftment, proliferation, function and whole body distribution of the cellular transplants in a preclinical porcine model with excellent translational potential to humans; 2) develop and validate the application of state-of-the-art imaging technologies facilitating the provision of new regenerative therapies to preclinical large animal models and patients; 3) directly contribute to the opening of a new market sector for i) imaging equipment (SPECT, PET/MR, optoacoustic imaging in preclinical large animal models and patients), ii) nano-imaging molecule supplies (nanomolecules allowing multimodality imaging of specific cell types with high sensitivity), iii) validated transplantable in vitro differentiated human beta-cells and porcinexenotransplant islets thus will reinforce the European healthcare supply chain for regenerative medicinal products. The iNanoBIT project will provide the currently missing toolbox for preclinical/clinical testing for a safe translation of regenerative medicinal cellular and tissue products, currently under preclinical and clinical trials, which is vital for the competitiveness of the European healthcare sector in this fast-growing area. The consortium of 5 SME and 3 Academic partners is coordinated and driven by the industrial partners from the field of nanotechnology, imaging and stem cell technologies, providing a perfect match and unique combination addressing the scope and expected impact of the call and providing TRL 3/4 starting points for the key technological elements, and expect to arrive to TRL6 levels of validated technologies ready for marketing by the end of the project.

Collaborating partners in the project: